ライフサイエンスコーパス: voiding dysfunction

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 offers promise for managing both storage and voiding dysfunction.

2 th overactivity syndromes and nonobstructive voiding dysfunction.

3 ck therapy for the treatment of recalcitrant voiding dysfunction.

4 reatment of benign prostatic hyperplasia and voiding dysfunction.

5 rned voiding patterns that contribute to the voiding dysfunction.

6 basis of lower renal tract malformations and voiding dysfunction.

7 Voiding dysfunction after anti-incontinence procedures i

8 le of preoperative urodynamics in predicting voiding dysfunction after anti-incontinence surgery is r

9 of the urothelial barrier, a major cause of voiding dysfunction and bladder pain syndrome.

10 so assessed postoperative urge incontinence, voiding dysfunction, and adverse events.

11 lications (urinary tract infection, urgency, voiding dysfunction, and mesh erosion) were more common

12 eye movement behaviour disorder and urinary voiding dysfunction appear to precede the development of

13 urinary-tract infection, hydronephrosis, and voiding dysfunctions as a result of neurogenic bladders.

14 5-HT3A mutant mice had marked voiding dysfunction characterized by a loss of micturiti

15 of clinical presentations such as hematuria, voiding dysfunction, flank pain, abdominal pain, nephrol

16 of women who appear to be at higher risk of voiding dysfunction following incontinence surgery, and

17 Urinary voiding dysfunction in childhood, manifesting as inconti

18 Voiding dysfunction in children encompasses a wide spect

19 Over the last several decades voiding dysfunction in children has primarily been assoc

20 This overview of voiding dysfunction in children outlines the established

21 ill focus on the diagnosis and management of voiding dysfunction in neurologically and anatomically n

22 tive urodynamics in predicting postoperative voiding dysfunction in patients undergoing anti-incontin

23 Several aspects of voiding dysfunction in women remain under investigation,

24 hough not useful in the primary treatment of voiding dysfunction is equivalent in potency to biofeedb

25 Voiding dysfunction may play an etiological role in cong

26 Voiding dysfunction may spontaneously improve or require

27 se medications in the treatment of pediatric voiding dysfunction, neurogenic bladder, chronic lower u

28 rates of positive provocative stress tests, voiding dysfunction, or adverse events.

29 prognostic information regarding the risk of voiding dysfunction postoperatively and the possibility

30 The rates of voiding dysfunction requiring surgery were 2.7% in those

31 afferent neurons may therefore contribute to voiding dysfunction seen in diabetes mellitus.

32 Voiding dysfunction typically presents after toilet trai

33 complications include but are not limited to voiding dysfunction, urinary retention, vaginal extrusio

34 igher rate of lower urinary tract injury and voiding dysfunction when compared with transobturator ta

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。